Israel Englander Celyad Oncology Sa Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.49 - $1.08 $5,386 - $11,872	10,993 New	10,993 $5,000
Q4 2020 Feb 16, 2021	SELL	$7.13 - $9.95 $90,094 - $125,728	-12,636 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$9.17 - $11.03 $32,260 - $38,803	-3,518 Reduced 21.78%	12,636 $126,000
Q2 2020 Aug 14, 2020	SELL	$7.07 - $12.46 $6,108 - $10,765	-864 Reduced 5.08%	16,154 $175,000
Q1 2020 May 14, 2020	SELL	$4.18 - $12.42 $3,904 - $11,600	-934 Reduced 5.2%	17,018 $124,000
Q4 2019 Feb 14, 2020	SELL	$8.46 - $12.74 $271,126 - $408,291	-32,048 Reduced 64.1%	17,952 $187,000
Q3 2019 Nov 14, 2019	BUY	$9.6 - $14.88 $480,000 - $744,000	50,000 New	50,000 $504,000
Q2 2019 Aug 14, 2019	SELL	$10.94 - $22.64 $297,327 - $615,309	-27,178 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$19.76 - $24.56 $1.25 Million - $1.56 Million	-63,419 Reduced 70.0%	27,178 $554,000
Q4 2018 Feb 14, 2019	BUY	$16.0 - $28.17 $594,736 - $1.05 Million	37,171 Added 69.57%	90,597 $1.65 Million
Q3 2018 Nov 14, 2018	BUY	$26.49 - $31.86 $917,746 - $1.1 Million	34,645 Added 184.47%	53,426 $1.41 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $35.15 $489,245 - $660,152	18,781 New	18,781 $582,000

Ticker CYAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,594,000
Market Cap $11.7M
Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.